Growing Immunization Programs and Campaigns are driving the Growth of Middle East and Africa Animal and Human Vaccines Market

Implementing a robust immunization program in Middle Eastern and African countries is vital for enhancing public health and preventing the spread of infectious diseases. To ensure the success of such initiatives, it is crucial to undertake comprehensive awareness campaigns. Immunization programs and campaigns are increasing worldwide because of the increasing number of chronic diseases. There is an urgent need to increase awareness regarding vaccination that can be achieved by launching several campaigns and programs, as hepatitis, diphtheria, pertussis, and polio, among other infectious diseases, are prevailing in the environment. This has been reported that the number of immunization programs is increasing with an increase in infectious diseases. Along with this, immunization coverage is also increasing worldwide intending to fight against debilitating diseases.

Access Full Report @ https://www.databridgemarketresearch.com/reports/middle-east-and-africa-animal-and-human-vaccines-market

Data Bridge Market Research analyzes that the Middle East and Africa Animal and Human Vaccines Market is expected to reach USD 5,358,452.80 thousand by 2031 from USD 3,480,103.50 thousand in 2023, growing at a CAGR of 5.6% in the forecast period of 2024 to 2031.

Key Findings of the Study

Growing Prevalence of Chronic Conditions

The prevalence of infectious diseases is increasing worldwide and this has been seen that flu and bacterial infectious diseases are surging at a rapid rate. This increasing rate of infectious diseases has created the need for disease prevention which can be prevented by vaccination or immunization. There is an urgent need for mass vaccination, as diseases are increasing at a significant rate. Mass vaccination require a large amount of vaccine disease, hence expected to provide the market with lucrative growth. The prevalence of growing chronic diseases worldwide has significantly heightened the demand for vaccines, thereby expanding the vaccine market. Chronic diseases, such as Flu, impose a substantial health burden globally. In response to this escalating health challenge, there is a growing recognition of the preventive role that vaccines can play in reducing the incidence and severity of various chronic illnesses

Report Scope and Market Segmentation

Segment Analysis

The Middle East and Africa animal and human vaccines market is categorized into three notable segments based on type, end user, and distribution channel.

• On the basis of type, the Middle East and Africa animal and human vaccines market is segmented into human and animal

In 2024, the human segment is expected to dominate the Middle East and Africa animal and human vaccines market

In 2024, the human segment is expected to dominate the market with 86.09% market share due to the rapid development of human vaccines.

• On the basis of end user, the Middle East and Africa animal and human vaccines market is segmented into hospitals, clinics, and others

In 2024, the hospitals segment is expected to dominate the Middle East and Africa animal and human vaccines market

In 2024, the hospitals segment is expected to dominate the market with a 80.14% market share as the majority of the vaccination is provided by the government authority or regulatory bodies and the rising vaccination programs to decrease the disease burden.

• On the basis of distribution channel, the Middle East and Africa animal and human vaccines market is segmented into direct tenders, retail sales, and others. In 2024, the direct tenders segment is expected to dominate the market with a market share of 85.19%

Major Players

Data Bridge Market Research analyses GSK plc. (U.K.), Merck & Co., Inc. (U.S.), Sanofi (France), Boehringer Ingelheim International GmbH (Germany), and Ceva Santé Animale (France) as the major players in the Middle East and Africa animal and human vaccines market.

Market Development

• In January 2023, Senvelgo, the recent innovation from Boehringer Ingelheim, has secured the prestigious Animal Health Best New Product for Companion Animals award. This accolade recognizes Senvelgo for its remarkable contribution to simplifying and enhancing the treatment of diabetic cats. Boehringer Ingelheim's commitment to innovation is evident in Senvelgo, offering a solution that is not only simple and safe but also highly convenient for both feline patients and their caregivers
• In 2023, Merck & Co., Inc. received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients with FIGO 2014 Stage III-IVA cervical cancer. This approval is based on positive results from the Phase 3 KEYNOTE-A18 trial, where KEYTRUDA combined with CRT showed a 41% reduction in the risk of disease progression or death compared to a placebo plus CRT. The median progression-free survival (PFS) was not reached in either group. This marks the third indication for KEYTRUDA in cervical cancer, emphasizing its effectiveness, and it is the 39th overall indication for KEYTRUDA in the United States. This milestone underscores Merck's commitment to advancing treatment options for patients with various types of cancer
• In July 2023, Biogenesis Bago announced BIOAFTOGEN under the Food and Agriculture Organization of the United Nations (FAO). This marks a historic moment as BIOAFTOGEN becomes the first FMD vaccine to receive such prequalification. This achievement enhances the company´s position as a global leader in FMD prevention and reinforces its commitment to collaboration with leading technical and scientific organizations, contributing to food safety and animal health status worldwide
• In November 2020, GSK plc. along with Medicines for Malaria Venture presented positive data (TEACH study) of tafenoquine used for the treatment of Plasmodium vivax malaria in children and adolescents. During the four months of examination, 95% of study’s 60 subjects did not show signs of Plasmodium vivax malaria. The results were presented through a virtual annual meeting of the American Society of Tropical Medicine & hygiene 2020. This has helped the company to move forward on the product for the treatment of malaria and to provide evidence of their product
• In November 2020, Sanofi received approval from the European Commission for Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza disease in adults aged 18 years or older. This approval helped the company to advance its product portfolio involving vaccines and to strengthen its roots in the European vaccine market

Regional Analysis

Geographically, the countries covered in the Middle East and Africa animal and human vaccines market report are Saudi Arabia, Egypt, U.A.E., Israel, Iran, Iraq, Oman, Kuwait, Qatar, Bahrain, Yemen, Jordan, Lebanon, Palestine, rest of Middle East, South Africa, Nigeria, Ethiopia, Tanzania, Kenya, Algeria, Ghana, Mozambique, Uganda, Democratic Republic of Congo, Sudan, Morocco, Angola, Madagascar, Malawi, Zambia, Ivory Coast, Cameroon, Zimbabwe, Libya, Chad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Comoros, Seychelles, and rest of Africa.

As per Data Bridge Market Research analysis:

Africa is estimated to be the dominant and fastest growing region in the Middle East and Africa animal and human vaccines market

Africa is expected to dominate the market and is estimated to be the fastest growing region due to the presence of the largest consumer market and increasing government support and funding.

For more detailed information about the Middle East and Africa animal and human vaccines market report, click here – https://www.databridgemarketresearch.com/reports/middle-east-and-africa-animal-and-human-vaccines-market